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Changes in gene copy numbers are often associated with solid tumors, including breast cancer. Because overexpression of epidermal growth factor receptor (EGFR) and protein kinase B (AKT1) is also observed in breast cancer, Li *et al*. undertook this study to determine the rate of *EGFR* and *AKT1* gene copy number alterations in breast cancer and their performance as prognostic factors. Half of the samples they analyzed contained alterations in gene copy number of *EFGR*, *AKT1*, or both. High copy number of *EGFR*, but not *AKT1*, was associated with poor 5-year overall survival; the prognosis for patients with high copy numbers of both *EGFR* and *AKT1* was even worse. These findings present the opportunity for targeting treatment against EGFR and AKT1 to improve survival.doi:
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The estrogen (E2)--estrogen receptor-α (ER(α)) complex interacts with growth factors and plays a critical role in activating signaling pathways that are upregulated in breast cancer, making it an obvious target in therapy. However, many patients develop resistance to anti-estrogen therapies. Yoshimaru *et al*. have previously established that ERalpha activity-regulator synthetic peptide (ERAP) activates the tumor suppressor prohibitin 2 against E2-dependent ER(α) activity. Here, they further show that ERAP can block the activity of signaling pathways induced by E2--ER(α) and growth factor interactions in anti-E2-resistant breast cancer cells. These results suggest that ERAP, especially in combination with anti-E2 therapies, can have a potent antitumor effect on resistant cancer cells.doi:
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In this review, Nishimura *et al*. describe current and emerging advances in tumor-associated antigen (TAA)-derived peptide vaccine therapy, an effective and promising cancer immunotherapy agent. A handful of clinical trials have indicated the partial clinical benefit of TAA-derived short peptide vaccines, which are presented by potentially all nucleated cells. These vaccines initiate CTL responses to a number of different tumor types. More recent work has revealed the potency of TAA-derived long peptide vaccines, which are processed and presented by professional antigen-presenting cells, activating both CTL and T-helper cell responses important for induction of more potent antitumor immunity. These vaccines represent a new form of targeted therapy to improve survival in patients undergoing treatment for a variety of cancers.doi:
